OBIO Orchestra BioMed Holdings, Inc. Ordinary Shares
XNAS 5.54 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
OBIO
$5.54
—
Key stats
$5.54
- 52-Week Range
- $3.46 – $6.50
- YTD
- +28.65%
- IV Rank (30D)
- 15.09
- Straddle Price
- $1.27
- P/C Vol Ratio
- 0.01
- Market Cap
- $0.3B
- Open
- $5.58
- Day Range
- $5.52 – $5.66
- Volume
- 242,656
- Prev Close
- $5.59
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.27 |
| Cost of Equity (CAPM) | 11.92% (VRP-adj) |
| WACC | 11.44% |
| Volatility Risk Premium | +127.5pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -308.3% |
| Book / Price | 8.8% |
| Gross Margin (TTM) | 99.5% |
| FCF Margin (TTM) | -184.8% |
| Debt / Equity | 1.18 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $5.66 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $5.81 |
| Bollinger Width / SMA20 | 276.7% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $0B |
Peers used for multiples: ABEO, ACHV, CLDX, CORT, DCTH, KYTX, MIST, PHAT
60-Day Conviction
6%
20-Day Fair Value
≈ by Nov 25, 2026
$5.57
α +0.3%
rank 47%
conviction
21%
40-Day Fair Value
≈ by Dec 24, 2026
$5.62
α +1.3%
rank 52%
conviction
45%
60-Day Fair Value
≈ by Jan 22, 2027
$5.56
α +0.2%
rank 44%
conviction
6%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $1.57 | 50% | median 3.2× · 5 peers |
| Peer P/S | $5.58 | 50% | median 10.5× · 6 peers |
| Market Anchor (SMA50) | $5.66 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 86
- List Date
- 2023-01-27
- CIK
- 0001814114
- Next Earnings
- 2026-11-09
- EPS Forecast
- ($0.40) (4 est.)
- Headquarters
- New Hope, PA
- Homepage
- https://www.orchestrabiomed.com
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through ris…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -24.35% | -19.36% | -2.60% | -19.03% | -16.34% |
| Feb | 10.26% | -14.13% | -15.95% | 8.96% | -2.71% |
| Mar | 95.31% | -23.18% | 4.39% | -2.97% | 18.39% |
| Apr | -12.93% | -10.91% | -8.33% | -8.06% | -10.06% |
| May | -0.46% | 57.50% | 3.64% | -1.51% | 14.79% |
| Jun | -57.16% | 14.15% | -15.19% | 12.66% | -11.38% |
| Jul | -11.20% | 3.65% | 10.47% | -7.76% | -1.21% |
| Aug | 13.45% | -2.19% | 11.89% | 22.33% | 11.37% |
| Sep | 39.30% | -18.02% | -9.49% | 26.94% | 9.68% |
| Oct | -45.59% | 5.10% | 52.94% | -12.60%* | -0.04% |
| Nov | 32.34% | 6.43% | 34.68% | -- | 24.48% |
| Dec | 34.07% | -31.27% | -16.83% | -- | -4.68% |
| Total | -18.05% | -45.56% | 31.97% | 9.33% | -5.58% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $5.81
SMA 50: $5.66
SMA 200: $4.51
Current: $5.55
EMA 12: $5.68
EMA 26: $5.70
MACD: -0.0240 | Signal: -0.0535
BULLISH
ADX (14): 16.51
RANGE
+DI: 16.92
−DI: 18.93
Momentum Oscillators
RSI (14): 46.23
NEUTRAL
Stoch %K: 20.83
Stoch %D: 26.24
Williams %R: -77.50
Volume & Volatility
BB Upper: $6.27
BB Lower: $5.34
NEUTRAL
OBV: 20,426,751
Vol SMA 20: 326,458
Vol ROC: 1.96%
ATR: $0.34
True Range: $0.14
HV 20: 51.9%
HV 30: 49.5%
HV 60: 63.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Strong recent news sentiment, with multiple positive headlines highlighting the company's clinical trial updates and regulatory approvals.
- Trend indicators suggest a bullish trend, with the stock above its short-term moving averages and the MACD indicating a bearish momentum signal.
Primary Risks:
- High volatility, with a beta of 2.23, indicating that the stock moves more than the market.
- Options market pricing a significant move by expiration, which could lead to increased uncertainty and potential price swings.
Investment Thesis:
Orchestra BioMed (OBIO) is a biotech company with a strong pipeline of clinical trials and regulatory approvals. The recent news headlines have been overwhelmingly positive, suggesting that the company's AVIM therapy may have substantial and sustained benefits for patients. While there are some risks associated with high volatility and options market expectations, we believe that OBIO has significant potential for growth and upside.
Recent News Sentiment Impact:
The recent news headlines have had a strong impact on OBIO's stock price, driving the stock higher as investors become more optimistic about the company's prospects. The positive sentiment is likely to continue, at least in the short term, unless there are some negative developments or unexpected setbacks.
Technical Analysis
Trend Direction: Medium-term (1-3 months) bullish trend
Support/Resistance Levels:
- Short-term support: $4.00 (SMA 20)
- Medium-term resistance: $4.19 (Upper Bollinger Band)
Momentum Signals:
- RSI interpretation: Neutral (49.51), indicating that the stock is not overbought or oversold.
- MACD signal: Bearish (indicating a potential sell signal).
- Bollinger Bands position: Neutral, with the price touching the middle band.
Volume Analysis:
- Volume trends: Increased volume on the recent upmove, suggesting institutional interest and buying pressure.
- Institutional interest signals: High put/call ratio (0.50) suggests that investors are positioning for a potential pullback.
News & Sentiment Analysis
Recent Headlines Summary:
Multiple positive headlines highlighting clinical trial updates and regulatory approvals.
Sentiment Assessment:
Aggregate sentiment is POSITIVE, with all recent news headlines reporting on the company's progress in its clinical trials and regulatory approvals.
Catalyst Identification:
- Upcoming institutional investor conferences
- Pivotal IDE Coronary Trial results
Market Narrative:
The market narrative is one of optimism and growing interest in OBIO's AVIM therapy. The positive sentiment is likely to continue unless there are some negative developments or unexpected setbacks.
Risk & Volatility Assessment
Beta Interpretation:
High volatility, with a beta of 2.23, indicating that the stock moves more than the market.
Volatility Regime:
Current volatility regime is high, with an IV rank of 25.4% and expected move by expiration of $1.27.
Options Market Signals:
- IV rank: Medium (25.4%)
- Put/call ratio: Bullish (0.50)
- Unusual activity: None reported
Downside Protection:
Support levels are in place at $4.00 (SMA 20), with a potential risk management strategy involving stop-loss orders and position sizing considerations.
Market Context & Positioning
Sector Performance:
OBIO is outperforming the broader biotech sector, which is experiencing some volatility.
Institutional Activity:
Increased institutional interest and buying pressure are evident in the options market, suggesting that investors are positioning for a potential long-term uptrend.
Correlation Analysis:
Correlation with the SPY index is moderate (0.36), indicating that OBIO's stock price moves somewhat independently of the broader market.
Relative Valuation:
OBIO is trading within a range, with some room to move higher before reaching its upper resistance level.
Key Levels & Action Items
Critical Price Levels:
- Short-term support: $4.00 (SMA 20)
- Medium-term resistance: $4.19 (Upper Bollinger Band)
Breakout/Breakdown Levels:
- Potential breakout above $4.19
- Potential breakdown below $3.99 (SMA 50)
Time-Sensitive Catalysts:
- Upcoming institutional investor conferences
- Pivotal IDE Coronary Trial results
Risk Management:
Stop-loss orders and position sizing considerations are recommended to manage potential risks associated with high volatility and options market expectations.
Conclusion
OBIO is a biotech company with significant potential for growth and upside, driven by its strong pipeline of clinical trials and regulatory approvals. While there are some risks associated with high volatility and options market expectations, we believe that OBIO has the potential to continue moving higher in the short term. A comprehensive risk management strategy is recommended to manage potential risks and capitalize on opportunities as they arise.
Generated
News
All OBIO news →
OBIO Options Activity & IV Rank
OBIO IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 107.5%
7-DTE IV: —
Expected Move: $1.27
7-DTE Move: $1.27
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 129
Put Volume: 1
P/C Volume: 0.008
BULLISH
Call OI: 801
Put OI: 239
P/C OI: 0.298
Total OI: 1,040
ATM Options Pricing
ATM Call: $0.78
ATM Put: $0.50
Call %: 14.0%
Put %: 9.0%
Chain Summary
Chain Volume: 167
Chain OI: 2,158
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 47th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
47%
vs own history
GEX tilt
+0.34
OI-weighted, today
Vanna tilt
-0.68
δ-sensitivity to IV
Charm tilt
+0.58
δ-decay vs time
Vanna tilt -0.68: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.58: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 107.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)15.1LowOct 26
Straddle Price (30 DTE)$1.27Oct 26
Beta Analysis
Risk Metrics
Beta: 1.4279
Alpha: 35.50%
Correlation: 0.2816
R-Squared: 7.9%
Stock Volatility: 64.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own OBIO
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $388K | #2699 of 3138 | +26.9% | 13F | |
| Citadel Hedge fund Ken Griffin | $242K | #5287 of 6285 | -29.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
OBIO Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 60,223,538 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$52.21K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $52.21K | 100.00% | 2026-06-30 |
2 filers$125.14K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $75.94K | 60.69% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $49.19K | 39.31% | 2026-06-30 |
OBIO Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Darren Sherman | See Remarks | Sell (S) | −15,000 | $6.36 | -$95.4K | EDGAR |
| 2026-09-11 | David P Hochman | See Remarks | Tax (F) | −6,566 | $5.81 | -$38.1K | EDGAR |
| 2026-09-08 | David P Hochman | See Remarks | Buy (P) | +10,000 | $4.79 | $47.9K | EDGAR |
| 2026-09-02 | Darren Sherman | See Remarks | Sell (S) | −15,000 | $4.94 | -$74.1K | EDGAR |
| 2026-08-28 | Joshua Aiello | Principal Accounting Officer | Tax (F) | −203 | $5.26 | -$1.1K | EDGAR |
| 2026-08-28 | Andrew Lawrence Taylor | Chief Financial Officer | Tax (F) | −3,076 | $5.26 | -$16.2K | EDGAR |
| 2026-08-28 | Darren Sherman | See Remarks | Mixed | −2,925 | $5.28 | -$15.2K | EDGAR |
| 2026-08-14 | John Prosper Mack | Director | Tax (F) | −4,885 | $4.42 | -$21.6K | EDGAR |
| 2026-08-14 | Chris Cleary | Director | Tax (F) | −4,238 | $4.42 | -$18.7K | EDGAR |
| 2026-08-14 | Eric S Fain | Director | Tax (F) | −5,145 | $4.42 | -$22.7K | EDGAR |
| 2026-08-14 | David Pacitti | Director | Tax (F) | −3,761 | $4.42 | -$16.6K | EDGAR |
| 2026-08-04 | Darren Sherman | See Remarks | Sell (S) | −15,000 | $4.09 | -$61.4K | EDGAR |
| 2026-07-02 | Darren Sherman | See Remarks | Sell (S) | −15,000 | $4.27 | -$64.0K | EDGAR |
| 2026-06-25 | Jason Aryeh | Director | Grant (A) | +42,553 opt | — | EDGAR | |
| 2026-06-25 | John Prosper Mack | Director | Mixed | +31,143 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
OBIO Insider Holdings
13 insiders · @ $5.55
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Roderick Wong | 10%+ Owner | 9,556,063 | $53.04M | -$264 | 4 | 2026-04-29 |
| 2 | RTW INVESTMENTS, LP | 10%+ Owner | 8,306,063 | $46.10M | $551.4K | 2 | 2025-05-01 |
| 3 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 10%+ Owner | 5,292,556 | $29.37M | $5.78M | 1 | 2025-08-05 |
| 4 | Darren Sherman | See Remarks | 1,121,402 | $6.22M | -$529.3K | 26 | 2026-10-02 |
| 5 | David P Hochman | See Remarks | 1,070,603 | $5.94M | $356.7K | 31 | 2026-09-11 |
| 6 | Andrew Lawrence Taylor | Chief Financial Officer | 589,989 | $3.27M | $9.9K | 16 | 2026-08-28 |
| 7 | Jason Aryeh | Director | 118,118 | $655.6K | $39.9K | 13 | 2026-06-25 |
| 8 | Eric S Fain | Director | 107,130 | $594.6K | $58.8K | 15 | 2026-08-14 |
| 9 | John Prosper Mack | Director | 66,544 | $369.3K | $0 | 5 | 2026-08-14 |
| 10 | Pamela Ann Connealy | Director | 66,038 | $366.5K | $0 | 9 | 2026-06-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
OBIO Board & Officers
As of SEC filings through Oct 2, 2026Directors 8
- Darren Sherman · since Jan 26, 2023
- David P Hochman · since Jan 26, 2023
- Eric S Fain · since Jan 26, 2023
- Jason Aryeh · since Jan 26, 2023
- Pamela Ann Connealy · since Jan 26, 2023
- David Pacitti · since Mar 26, 2024
- John Prosper Mack · since Jul 29, 2024
- Chris Cleary · since Jan 30, 2025
Officers 4
- David P Hochman · Chief Executive Officer and Chairperson · since Jan 26, 2023
- Darren Sherman · President and Chief Operating Officer · since Jan 26, 2023
- Andrew Lawrence Taylor · Chief Financial Officer · since Jun 6, 2023
- Joshua Aiello · Principal Accounting Officer · since Jan 26, 2023
10% owners 2
- Roderick Wong · listed since Jan 2023
- Rtw Investments, LP (entity) · since Jan 24, 2023
Changes in the last 10 years (45)
| Aug 5, 2025 | Perceptive Life Sciences Master Fund Ltd reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2025 | Perceptive Advisors LLC reported in an SEC filing no longer being a 10% owner |
| Aug 5, 2025 | Joseph Edelman reported in an SEC filing no longer being a 10% owner |
| Jan 30, 2025 | The company announced the departure of Eric A Md Rose from the board in an SEC filing |
| Jan 30, 2025 | Chris Cleary became a director |
| Aug 7, 2024 | HSAC 2 Holdings, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 29, 2024 | John Prosper Mack became a director |
| Jul 11, 2024 | Perceptive Life Sciences Master Fund Ltd became a 10% owner |
| Jul 11, 2024 | Perceptive Advisors LLC became a 10% owner |
| Jul 11, 2024 | Joseph Edelman became a 10% owner |
| Mar 26, 2024 | David Pacitti became a director |
| Sep 19, 2023 | George Papandreou became General Manager and Senior Vice President, Focal Therapies |
| Jun 6, 2023 | Andrew Lawrence Taylor became Chief Financial Officer |
| Jun 5, 2023 | The company announced the departure of Michael Kaswan as Chief Financial Officer in an SEC filing |
| Jun 1, 2023 | William Reed Little became Executive Vice President, Corporate Development & Strategy |
| May 5, 2023 | Yuval Mika no longer listed as a director in SEC filings |
| Jan 30, 2023 | Yuval Mika first on file as a director |
| Jan 30, 2023 | Roderick Wong no longer listed as a director in SEC filings |
| Jan 30, 2023 | Roderick Wong no longer listed as Chief Executive Officer in SEC filings |
| Jan 26, 2023 | Yuval Mika became General Manager and Chief Technology Officer, Bioelectronic Therapies |
| Jan 26, 2023 | Roderick Wong first listed as a 10% owner in an SEC filing |
| Jan 26, 2023 | Pamela Ann Connealy became a director |
| Jan 26, 2023 | Michael Kaswan became Chief Financial Officer |
| Jan 26, 2023 | Medtronic plc became a 10% owner |
| Jan 26, 2023 | Joshua Aiello became Principal Accounting Officer |
| Jan 26, 2023 | Jason Aryeh became a director |
| Jan 26, 2023 | Geoffrey Wade Smith became a director |
| Jan 26, 2023 | Eric S Fain became a director |
| Jan 26, 2023 | Eric A Md Rose became a director |
| Jan 26, 2023 | David P Hochman became a director |
| Jan 26, 2023 | David P Hochman became Chief Executive Officer and Chairperson |
| Jan 26, 2023 | Darren Sherman became a director |
| Jan 26, 2023 | Darren Sherman became President and Chief Operating Officer |
| Jan 24, 2023 | Rtw Investments, LP became a 10% owner |
| Aug 3, 2020 | Stuart Walter Peltz became a director |
| Aug 3, 2020 | Stephanie A Sirota became VP-Corp Strategy & Corp Comms. |
| Aug 3, 2020 | Roderick Wong became a director |
| Aug 3, 2020 | Roderick Wong became Chief Executive Officer |
| Aug 3, 2020 | Pedro P Granadillo became a director |
| Aug 3, 2020 | Naveen Yalamanchi became a director |
| Aug 3, 2020 | Naveen Yalamanchi became Chief Financial Officer |
| Aug 3, 2020 | Michael Burkes Brophy became a director |
| Aug 3, 2020 | HSAC 2 Holdings, LLC became a 10% owner |
| Aug 3, 2020 | Carsten Boess became a director |
| Aug 3, 2020 | Alice Lee became VP Operations, Sec & Treasurer |
Not reported recently (12)
- William Reed Little · Last reported as Executive Vice President, Corporate Development & Strategy in an SEC filing dated Jun 3, 2024
- Yuval Mika · Last reported as General Manager and Chief Technology Officer, Bioelectronic Therapies in an SEC filing dated May 10, 2024
- George Papandreou · Last reported as General Manager and Senior Vice President, Focal Therapies in an SEC filing dated May 10, 2024
- Medtronic plc · Last reported as a 10% owner in an SEC filing dated Feb 14, 2024
- Geoffrey Wade Smith · Last reported as a director in an SEC filing dated Jul 24, 2023
- Pedro P Granadillo · Last reported as a director in an SEC filing dated Aug 10, 2020
- Stuart Walter Peltz · Last reported as a director in an SEC filing dated Aug 10, 2020
- Michael Burkes Brophy · Last reported as a director in an SEC filing dated Aug 10, 2020
- Carsten Boess · Last reported as a director in an SEC filing dated Aug 10, 2020
- Alice Lee · Last reported as VP Operations, Sec & Treasurer in an SEC filing dated Aug 6, 2020
- Stephanie A Sirota · Last reported as VP-Corp Strategy & Corp Comms. in an SEC filing dated Aug 6, 2020
- Naveen Yalamanchi · Last reported as a director in an SEC filing dated Aug 3, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
OBIO Proposed Insider Sales (Form 144)
Latest: 2026-10-01
? Form 144 Guide
Last 30d:
1 filing
· $94K notice value
· Last 90d:
3 filings
· $231K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Sherman Darren (3, $231K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-01 | Sherman Darren | Officer, Director | 15,000 | $94.0K | 2026-10-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-01 | Sherman Darren | Officer, Director | 15,000 | $75.3K | 2026-09-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-03 | Sherman Darren | Officer, Director | 15,000 | $61.3K | 2026-08-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-07-01 | Sherman Darren | Officer, Director | 15,000 | $64.8K | 2026-07-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-01 | Sherman Darren | Officer, Director | 15,000 | $58.0K | 2026-06-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-06-26 | Fain Eric S | Director | 2,683 | $8.2K | 2025-06-26 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-09-10 | Fain Eric S | Director | 1,800 | $9.6K | 2024-09-10 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-09-10 | Sherman Darren | Officer, Director | 6,904 | $36.6K | 2024-09-10 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-09-09 | Fain Eric S | Director | 1,800 | $9.8K | 2024-09-09 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-09-09 | Sherman Darren | Officer, Director | 6,804 | $37.3K | 2024-09-09 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
21 ETFs hold OBIO
21 shown · $24.41M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $9.1M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $5.3M | $74.6B | 2026-10-23 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $3.0M | — | 2026-09-30 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.02% | $2.1M | $13.7B | 2026-10-23 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.4M | — | 2026-09-30 |
| 6 | SURI Simplify Propel Opportunities ETF | Nport | 1.23% | $946,655 | — | 2026-06-30 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.00% | $697,239 | — | 2026-05-31 |
| 8 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.06% | $684,747 | $1.2B | 2026-10-23 |
| 9 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.04% | $394,179 | $1.0B | 2026-10-23 |
| 10 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.02% | $276,205 | — | 2026-09-30 |
| 11 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $170,617 | — | 2026-05-31 |
| 12 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $106,566 | — | 2026-10-26 |
| 13 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.02% | $25,820 | — | 2026-10-24 |
| 14 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $24,874 | — | 2026-09-30 |
| 15 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $17,787 | $3.2B | 2026-10-23 |
| 16 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.01% | $13,326 | — | 2026-10-26 |
| 17 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $12,648 | — | 2026-10-26 |
| 18 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $9,696 | — | 2026-10-26 |
| 19 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $6,815 | — | 2026-10-26 |
| 20 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $266 | — | 2026-10-26 |
| 21 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.01% | $83 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.01
TTM Revenue
$31.98M
TTM Net Income
$-59.57M
TTM Op. Cash Flow
$-58.32M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $88.00K | $-24.08M | $-0.38 | $-19.33M |
| Q1 '26 | 2026-03-31 | $110.00K | $-20.66M | $-0.33 | $-22.17M |
| Q4 '25 | 2025-12-31 | $30.92M | $5.99M | $0.26 | $-2.27M |
| Q3 '25 | 2025-09-30 | $861.00K | $-20.83M | $-0.40 | $-14.55M |
| Q2 '25 | 2025-06-30 | $836.00K | $-19.36M | $-0.50 | $-15.53M |
| Q1 '25 | 2025-03-31 | $868.00K | $-18.75M | $-0.49 | $-16.62M |
| Q4 '24 | 2024-12-31 | $253.00K | $-16.16M | $-0.43 | $-13.54M |
| Q3 '24 | 2024-09-30 | $987.00K | $-15.43M | $-0.41 | $-13.70M |
| Q2 '24 | 2024-06-30 | $778.00K | $-15.98M | $-0.45 | $-10.21M |
| Q1 '24 | 2024-03-31 | $620.00K | $-13.46M | $-0.38 | $-13.11M |
| Q4 '23 | 2023-12-31 | $262.00K | $-12.82M | $-0.37 | $-10.97M |
| Q3 '23 | 2023-09-30 | $419.00K | $-13.32M | $-0.38 | $-10.28M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
11.36
P/S
10.45
EV/EBITDA
—
EV/Sales
10.90
ROE
-202.5%
ROA
-51.5%
Div Yield
0.00%
FCF Yield
-17.45%
Debt/Equity
1.18
Current Ratio
—
Market Cap
$334.24M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.55M
SI % of Float
8.13%
Days to Cover
6.98
Short Vol Ratio
67.3%
Free Float
31.33M
Float %
52.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22